摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Hydroxy-N-methyltyrosine--hydrogen chloride (1/1) | 51912-15-3

中文名称
——
中文别名
——
英文名称
3-Hydroxy-N-methyltyrosine--hydrogen chloride (1/1)
英文别名
3-(3,4-dihydroxyphenyl)-2-(methylamino)propanoic acid;hydrochloride
3-Hydroxy-N-methyltyrosine--hydrogen chloride (1/1)化学式
CAS
51912-15-3
化学式
C10H14ClNO4
mdl
——
分子量
247.67
InChiKey
WUBSGPKNROVQMZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.71
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    94.4
  • 氢给体数:
    4
  • 氢受体数:
    5

文献信息

  • Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
    申请人:——
    公开号:US20030236212A1
    公开(公告)日:2003-12-25
    The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    该发明涉及新型酰辅酶A类似物,包含酮化合物的组合物,以及用于治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法,包括给予含有酮化合物的组合物。该发明的酰辅酶A类似物、组合物和方法也适用于治疗和预防阿尔茨海默病、X综合征、过氧化物酶体增殖激活受体相关疾病、败血症、血栓性疾病、肥胖、胰腺炎、高血压、肾脏疾病、癌症、炎症、细菌感染和阳痿。在某些实施例中,该发明的酰辅酶A类似物、组合物和方法可与其他治疗药物(如降胆固醇和降血糖药物)联合治疗。
  • Urea and thiourea compounds and compositions for cholesterol management and related uses
    申请人:Dasseux Henri Jean-Louis
    公开号:US20050192347A1
    公开(公告)日:2005-09-01
    The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis/polymyalgia rheumatica/fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    本发明涉及新型尿素和硫脲化合物,包含尿素或硫脲化合物的组合物,以及用于治疗和预防衰老、阿尔茨海默病、癌症、心血管疾病、糖尿病肾病、糖尿病视网膜病变、葡萄糖代谢紊乱、血脂异常、脂蛋白异常、增强胆汁产生、增强逆向脂质转运、高血压、阳痿、炎症、胰岛素抵抗、胆汁中脂质的清除、调节C反应蛋白、肥胖、胆汁中氧固醇的清除、胰腺炎、帕金森病、过氧化物酶体增殖激活受体相关的疾病、胆汁中磷脂的清除、肾脏疾病、败血症、代谢综合征疾病(如X综合症)、血栓性疾病、胃肠道疾病、肠易激综合症(IBS)、炎症性肠病(如克罗恩病、溃疡性结肠炎)、关节炎(如类风湿性关节炎、骨关节炎)、自身免疫疾病(如系统性红斑狼疮)、硬皮病、强直性脊柱炎、痛风和假性痛风、肌肉疼痛:多发性肌炎/多发性肌痛症/纤维炎;感染和关节炎、儿童类风湿性关节炎、肌腱炎、滑囊炎和其他软组织风湿病的方法。在某些实施方式中,本发明的化合物、组合物和方法可与其他治疗药物(如降胆固醇和降血糖药物)联合治疗。
  • New imidazopyridine derivatives as angiotensin II antagonists
    申请人:J. URIACH & CIA. S.A.
    公开号:EP0669333A1
    公开(公告)日:1995-08-30
    The present invention relates to new imidazopyridine derivatives of formula I wherein: one of A, B, C and D is N and the other are CR, wherein each R independently represents hydrogen, C1-4 alkyl, COOH or halogen; R1 represents C1-4 alkyl or C3-7 cycloalkyl; Ar1 represents phenylene or pyridylene which can be optionally substituted; V represents C1-4 alkyl, C3-7 cycloalkyl, aryl, aryl-(C1-4)alkyl or a 5- or 6-membered aromatic heterocycle; the group X-Y represents C = C or CH-CR3; R3 represents hydrogen, C1-4 alkyl or aryl-(C1-4)alkyl; Z represents among others -CO2R4, -tetrazol-5-yl, -CONHS02R4, -CONR4R5, -CH2NHSO2R4; R4 and R5 independently represent hydrogen, C1-4 alkyl, aryl, aryl-(C1-4)alkyl or perfluoro-(C1-4)alkyl; W represents hydrogen, cyano, C1-4 alkyl, C1-4 haloalkyl, C3-7 cycloalkyl, aryl, aryl-(C1-4)alkyl, C1 -4 alkylsulfonyl, C1 -4 alkylsulfinyl, C1 -4 alkylthio, C1 -4 alkoxy, C1-4 alkylcarbonyl, halogen, hydroxymethyl or C1-4 alkoxymethyl, or W can have any of the meanings disclosed for Z. These compounds are angiotensin II antagonists.
    本发明涉及公式I的新咪唑吡啶衍生物,其中:A、B、C和D中的一个为N,另外三个为CR,其中每个R独立地代表氢、C1-4烷基、COOH或卤素;R1代表C1-4烷基或C3-7环烷基;Ar1代表苯基或吡啶基,可以选择性地被取代;V代表C1-4烷基、C3-7环烷基、芳基、芳基-(C1-4)烷基或5-或6-成员芳香杂环;X-Y基团代表C = C或CH-CR3;R3代表氢、C1-4烷基或芳基-(C1-4)烷基;Z代表等等的基团之一,如-CO2R4、-四唑-5-基、-CONHSO2R4、-CONR4R5、-CH2NHSO2R4;R4和R5独立地代表氢、C1-4烷基、芳基、芳基-(C1-4)烷基或全氟-(C1-4)烷基;W代表氢、氰基、C1-4烷基、C1-4卤代烷基、C3-7环烷基、芳基、芳基-(C1-4)烷基、C1-4烷基磺酰基、C1-4烷基亚砜基、C1-4烷基硫基、C1-4烷氧基、C1-4烷基羰基、卤素、羟甲基或C1-4烷氧甲基,或W可以具有Z所披露的任何含义。这些化合物是血管紧张素II拮抗剂。
  • Ketone compounds and compositions for cholesterol management and related uses
    申请人:——
    公开号:US20040198814A1
    公开(公告)日:2004-10-07
    The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    本发明涉及新型酮化合物、含有酮化合物的组合物,以及用于治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法,包括给予含有酮化合物的组合物。本发明的化合物、组合物和方法还可用于治疗和预防阿尔茨海默病、综合征X、过氧化物酶体增殖物激活受体相关疾病、败血症、血栓性疾病、肥胖、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施例中,本发明的化合物、组合物和方法可与其他治疗药物(如降胆固醇和降血糖药物)联合使用。
  • [EN] KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES<br/>[FR] COMPOSES A FONCTION CETONE ET COMPOSITIONS POUR LE CONTROLE DE CHOLESTEROL ET UTILISATIONS ASSOCIEES
    申请人:ESPERION THERAPEUTICS INC
    公开号:WO2005068412A1
    公开(公告)日:2005-07-28
    The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
    本发明涉及新型酮化合物、含有酮化合物的组合物,以及用于治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法,包括给予含有酮化合物的组合物。该发明的化合物、组合物和方法也适用于治疗和预防阿尔茨海默病、X综合征、过氧化物酶体增殖激活受体相关疾病、败血症、血栓性疾病、肥胖、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施例中,该发明的化合物、组合物和方法还适用于与其他治疗药物联合治疗,如降胆固醇和降糖药物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物